tiprankstipranks
Immunocore reports Q3 EPS 17c, consensus (35c)
The Fly

Immunocore reports Q3 EPS 17c, consensus (35c)

Reports Q3 revenue $80.2M, consensus $80.55M. “We are proud to report another strong quarter, marking two years of continuous growth for KIMMTRAK and another quarter of positive net income,” said Bahija Jallal, Immunocore’s (IMCR) Chief Executive Officer. “We are also making significant strides in advancing our broad pipeline – with brenetafusp in oncology, the HIV functional cure trial in infectious diseases, and in autoimmune diseases with tissue-targeted programs for type 1 diabetes and dermatologic diseases.”

Don't Miss our Black Friday Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App